000197572 001__ 197572
000197572 005__ 20230208173550.0
000197572 0247_ $$2CORDIS$$aG:(EU-Grant)732411$$d732411
000197572 0247_ $$2CORDIS$$aG:(EU-Call)H2020-ICT-2016-1$$dH2020-ICT-2016-1
000197572 0247_ $$2originalID$$acorda__h2020::732411
000197572 035__ $$aG:(EU-Grant)732411
000197572 150__ $$aPhotoacoustic/Ultrasound Mammoscopy for evaluating screening-detected abnormalities in the breast$$y2017-01-01 - 2021-06-30
000197572 371__ $$aIMASONIC SAS$$bIMASONIC$$dFrance$$vCORDIS
000197572 371__ $$aEKSPLA UAB$$bEKSPLA$$dLithuania$$ehttp://www.ekspla.com$$vCORDIS
000197572 371__ $$aSTICHTING MEDISCH SPECTRUM TWENTE$$bMST$$dNetherlands$$ehttp://www.mstwente.nl$$vCORDIS
000197572 371__ $$aTP21 GMBH$$bTP21$$dGermany$$ehttp://www.tp21.com$$vCORDIS
000197572 371__ $$aPA IMAGING R&D BV$$bPA IMAGING RD$$dNetherlands$$ehttp://www.PA-Imaging.com$$vCORDIS
000197572 371__ $$aUniversity of Bern$$bUB$$dSwitzerland$$ehttp://www.unibe.ch/eng/$$vCORDIS
000197572 371__ $$aUniversity of London - University College London$$bUCL$$dUnited Kingdom$$ehttp://www.ucl.ac.uk/$$vCORDIS
000197572 371__ $$aUniversity of Twente$$bUniversity of Twente$$dNetherlands$$ehttp://www.utwente.nl/en/$$vCORDIS
000197572 371__ $$aBrno University of Technology$$bBUT$$dCzechia$$ehttp://www.vutbr.cz/en/$$vCORDIS
000197572 372__ $$aH2020-ICT-2016-1$$s2017-01-01$$t2021-06-30
000197572 450__ $$aPAMMOTH$$wd$$y2017-01-01 - 2021-06-30
000197572 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000197572 680__ $$aX-ray mammography is the mainstay of breast cancer screening programs. It is estimated that between 20 - 50% of abnormal screening mammograms will prove to be negative. The paradigm in diagnosis is to establish whether a lesion is benign or malignant. All the imaging techniques conventionally used today – diagnostic x-ray, ultrasonography and magnetic resonance imaging have many limitations, leading to multiple and/or repeat imaging and often unnecessary biopsy. This leads to physical, psychological and economic burdens felt at individual, familial and societal levels.  

With an aging population, high incidence of breast cancer and tightening health-care budgets, there is an urgent  requirement for a non-invasive method for in-depth assessment of the screening-detected lesion. In PAMMOTH we will showcase such an imager, combining photoacoustic  and ultrasound imaging. With the use of quantitative image reconstruction of multi-wavelength photoacoustic data, information is gained of the vascular and oxygen status of the lesion relating to tumor physiology and function. From the ultrasound part, we derive ultrasound reflection from the lesion in a manner superior to conventional breast ultrasonography, relating to anatomic features and extent of a tumor. This information will enable the radiologist to come to a diagnosis accurately and rapidly without the use of contrast agents, without pain and  discomfort to the patient, while being cost-effective and not requiring complex infrastructure. 

Four excellent academic groups, three dynamic SMEs, and a hospital come together with support from key stakeholders in an Advisory group, to push beyond the state-of-the-art in science and technology to achieve the PAMMOTH imager. For the SMEs, in addition to tremendous improvements in individual product lines, the new integrated diagnostic imaging instrument opens up completely new market opportunities. 

We expect PAMMOTH to have a strong economic and clinical impact.
000197572 909CO $$ooai:juser.fz-juelich.de:822219$$pauthority$$pauthority:GRANT
000197572 909CO $$ooai:juser.fz-juelich.de:822219
000197572 970__ $$aoai:dnet:corda__h2020::46cc92eb8b4b85e6e35983ca70429560
000197572 980__ $$aG
000197572 980__ $$aCORDIS
000197572 980__ $$aAUTHORITY